Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VetoquinolSTU:8JM -1.77%87 3-1 Month Momentum % is 6.19% as of Sep. 08, 2026. GuruFocus rates STU:8JM with a GF Score™ of 87/100 and a GF Value™ of €84.92 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,017 Drug Manufacturers companies, Vetoquinol ranks better than 61.55% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-08), Vetoquinol's 3-1 Month Momentum % is 6.19%.
The industry rank for Vetoquinol's 3-1 Month Momentum % or its related term are showing as below:
STU:8JM's 3-1 Month Momentum % is ranked better than 61.55% of 1017
companies
in the Drug Manufacturers industry
Industry Median: 1.11
vs STU:8JM: 6.19
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Vetoquinol 3-1 Month Momentum % Related Terms
STU:8JM vs ZTS, UTHR, VTRS: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vetoquinol's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vetoquinol 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vetoquinol's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Vetoquinol's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vetoquinol (STU:8JM) has a 3-1 Month Momentum % of 6.19% as of Sep. 08, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Vetoquinol and its competitors. According to the industry distribution chart, Vetoquinol ranks #391 out of 1017 companies in the Drug Manufacturers industry, placing it in the top 38.4%.
Is Vetoquinol's 3-1 Month Momentum % too high?
Vetoquinol's current 3-1 Month Momentum % is 6.19%. The Drug Manufacturers industry median 3-1 Month Momentum % is 1.11. Vetoquinol's value of 6.19% is 457.7% above this industry median. Based on the distribution chart, Vetoquinol ranks #391 out of 1017 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vetoquinol has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vetoquinol's 3-1 Month Momentum % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vetoquinol ranks #391 out of 1017 companies for 3-1 Month Momentum %. This puts Vetoquinol in the upper half of its industry. The industry median 3-1 Month Momentum % is 1.11. Vetoquinol's value of 6.19% is 457.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
The median 3-1 Month Momentum % among Drug Manufacturers companies is 1.11, based on 1,017 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vetoquinol's current 3-1 Month Momentum % of 6.19% is 457.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Vetoquinol and its competitors. For the Drug Manufacturers industry, the median 3-1 Month Momentum % is 1.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vetoquinol's current 3-1 Month Momentum % is 6.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vetoquinol stock overvalued right now?
Based on GuruFocus' analysis, Vetoquinol (STU:8JM) is currently considered Modestly Undervalued. The stock's GF Value™ is €84.92, compared to a current price of €66.70 — trading 21.5% below its estimated fair value. The current 3-1 Month Momentum % is 6.19% and 457.7% above the Drug Manufacturers industry median of 1.11. Vetoquinol's overall GF Score™ is 87/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Vetoquinol (STU:8JM), the current 3-1 Month Momentum % is 6.19% as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vetoquinol (STU:8JM) Overvalued in 2026?
Based on GuruFocus' analysis, Vetoquinol stock appears to be undervalued.
The current stock price of €66.70 is trading 21.5% below its estimated GF Value™ of €84.92.
GuruFocus considers Vetoquinol to be Modestly Undervalued.
Key valuation signals for STU:8JM:
3-1 Month Momentum %: 6.19%
GF Value™: €84.92 vs. price of €66.70 (21.5% below fair value)
Industry Position: 457.7% above the Drug Manufacturers median (#391 of 1017)
No single metric tells the full story. See the STU:8JM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vetoquinol SA operates is a France-based firm serving in the healthcare market. Its focus lies on developing and marketing veterinary drugs mainly in the European region and to a certain extent in America and Asia. Its portfolio of drugs entails anti-infectives, anti- pain inflammatory drugs, cardiovascular and nephrology treatment intended mainly for pets and livestock.
87GF Score
Get the complete analysis for STU:8JM
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:8JM has been successfully added to your 
